Mymetics Corporation

$0.00+0.00%(+$0.00)
TickerSpark Score
47/100
Weak
87
Valuation
35
Profitability
60
Growth
24
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYMX research report →

52-Week Range50% of range
Low $0.00
Current $0.00
High $0.00

Companywww.mymetics.com

Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines.

CEO
Ronald Kempers
IPO
1999
Employees
2
HQ
Epalinges, CH

Price Chart

+0.00% · this period
$0.00$0.00$0.00May 19Nov 17May 19

Valuation

Market Cap
$46
P/E
-0.02
P/S
0.01
P/B
-0.00
EV/EBITDA
-36.02
Div Yield
0.00%

Profitability

Gross Margin
-47966.67%
Op Margin
-58166.67%
Net Margin
-160166.67%
ROE
7.69%
ROIC
-24.57%

Growth & Income

Revenue
$3.00K · 0.00%
Net Income
$-4,805,000 · -1.59%
EPS
$-0.02 · 32.77%
Op Income
$-1,745,000
FCF YoY
1.11%

Performance & Tape

52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
2.13
Avg Volume
1

Get TickerSpark's AI analysis on MYMX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 9, 15KEMPERS Ronald Hugo Gerardother5,000,000
Jan 31, 06Round Enterprises, Ltd.other0
Jan 31, 06Round Enterprises, Ltd.other0
Oct 4, 13Fleury Sylvainother800,000
Dec 31, 09Fleury Sylvainother350,000
Jun 18, 07Fleury Sylvainother0
Jun 17, 10Stegmann Antonius Johannesother4,000,000
Jun 17, 10Stegmann Antonius Johannesother150,000
Dec 27, 13KEMPERS Ronald Hugo Gerardsell3,000,000
Dec 27, 13KEMPERS Ronald Hugo Gerardother3,000,000

Our MYMX Coverage

We haven't published any research on MYMX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate MYMX Report →

Similar Companies